The Latest Cardiac and Vascular News
– ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated – ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen – Study findings warrant further clinical development of ION449 for patients with hypercholesterolemia at high cardiovascular risk CARLSBAD, Calif., April 4, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. […]
Clinical Study Confirms Ability to Identify Lung Congestion with Medical-Grade Accuracy TEL AVIV, Israel and WASHINGTON, D.C. – April 4, 2022 – Donisi Health, a MedTech company working to disrupt the readmission cycle of congestive heart failure (CHF) patients, announced results of a clinical study demonstrating the efficacy of its […]
Medtronic adds to its robust clinical program with long-term data demonstrating the continued blood pressure lowering effect of the Symplicity renal denervation procedure Medtronic also completes enrollment in the SPYRAL HTN-ON MED trial DUBLIN and WASHINGTON, April 4, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced long-term data […]
No Effect of Omecamtiv Mecarbil On Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction in METEORIC-HF Healthcare Resource Utilization and Cost Analysis from GALACTIC-HF Demonstrate Treatment with Omecamtiv Mecarbil Led to 19% Cost Reduction Per Patient in Key Subgroup Additional Results from GALACTIC-HF Indicate Treatment with Omecamtiv […]
New Analyses of thousands of patients spanning Phase 2 and pooled Phase 3 data demonstrate that NEXLETOL safely and significantly lowers LDL-C compared to placebo in patients with renal impairment or hypertension ANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today presented two new analyses from […]
Guidelines issued jointly by the American Heart Association, American College of Cardiology and Heart Failure Society of America New guidelines recommend the use of SGLT inhibitors for the prevention and treatment of heart failure and highlight the need to improve optimization of medical therapies during hospitalizations THE WOODLANDS, Texas, April 04, […]
– NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At Month 30, median change from baseline in NT-proBNP was -437 pg/mL with 68% of participants observing NT-proBNP levels below their baseline – Serum TTR levels were sustainably […]
Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs Data to be Presented Today at the American College of Cardiology 71st Annual Scientific Session & Expo CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a biotechnology company pioneering a new […]
AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of amyloid Sensitivity in those with previously diagnosed cardiac disease was 100% in ATTR and 93% in AL Cardiac uptake was also observed in eleven patients who had not previously been diagnosed with cardiac disease SAN FRANCISCO, April […]
Treatment with mavacamten showed sustained improvement in left ventricular outflow tract (LVOT) gradients, New York Heart Association (NYHA) Class and N-terminal pro brain natriuretic peptide (NT-proBNP) levels At 48 and 84 Weeks, Mavacamten safety was consistent with that seen in the EXPLORER-HCM study Interim results were presented as a late-breaking […]
